Wed.Apr 13, 2022

article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone.

Insurance 130
article thumbnail

The benefits of training in pharmaceutical microbiology

Pharmig

Everyone wants to know where they come from, and microbiologists are no different. But were we grown in a petri dish. The post The benefits of training in pharmaceutical microbiology appeared first on Pharmig.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

pharmaphorum

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech’s shares skywards. GSK is paying $55 per share in cash for Sierra – a 39% premium to its closing share price yesterday – which values the company at around $1.9 billion. Shares in Sierra were up 38% in pre-market trading this morning.

Vaccines 104
article thumbnail

RWE can boost trial acceleration, cost efficiency, and inclusivity

Outsourcing Pharma

An expert from trial tech specialist Komodo Health talks about how real-world evidence use could elevate study design, conserve costs, and improve recruitment.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

The value of coaching as part of an organisation’s DNA

pharmaphorum

Training can be a bore; dull, predictable sessions shoe-horned into the diary when a meeting room is available or via a virtual session full of muted moments and cross-talk confusion. The pharma industry has turned the microscope of every aspect of its delivery in the face of era-defining shifts caused by the pandemic, and now it is time focus on coaching staff to perform across a new sales and information-sharing landscape.

article thumbnail

Clinically Relevant Metoprolol Drug Interactions

Med Ed 101

I’ve done tons of posts on drug interactions over the years. I’ve dedicated a whole book to drug interactions in primary care AND drug-food interactions. I was recently asked about metoprolol drug interactions and which ones would I consider the most important? Here’s my list of metoprolol drug interactions that I think would be valid […].

45

More Trending

article thumbnail

Cannabis firm launches UK clinic following prescription license allocation

Pharma Times

Cantourage has appointed cannabis prescribers and is now officially operational via a new centre

48
article thumbnail

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

pharmaphorum

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, its other drug in the class. The results reported at the American Association of Cancer Research (AACR) meeting are from the REFINE trial of navitoclax alongside Novartis and Incyte’s JAK inhibitor Jakafi (ruxolitinib) in 34 patients with myelofibrosis who had not responded well to Jakafi on its own

52
article thumbnail

Ampersand Health and UCB partner in new arthritis initiative

Pharma Times

Companies will support a study which provides vital information on arthritis for patient-supporting HCPs

42
article thumbnail

J&J on the hook for $302m in pelvic mesh dispute

pharmaphorum

An appeals court in California has upheld a lower court ruling that ordered Johnson & Johnson to pay substantial penalties for deceptive marketing of its pelvic mesh implants used to treat conditions like pelvic organ prolapse. J&J and two Ethicon subsidiaries were held by the earlier ruling to have wilfully circulated misleading medical device instructions and marketing communications which “misstated, minimised, and/or omitted the health risks of Ethicon’s…pelvic mesh produ

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Novartis planning thousands of job cuts, say reports

pharmaphorum

Novartis has confirmed it is planning to reduce its headcount as part of a restructuring initiative announced last week, but has declined to put a figure on the cuts, as various media outlets suggest it could involve thousands of positions worldwide. The Swiss pharma group says it is “premature” to discuss the job losses until further progress is made on the reorganisation – which aims to carve $1 billion off Novartis’ costs within the next two years – but acknowledged that it

52